Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology Annual Meeting
December 07, 2021 at 08:00 am EST
Takeda Pharmaceutical Company Limited announced that it will present a total of 23 company-sponsored abstracts at the 63rdAmerican Society of Hematology (ASH) Annual Meeting being held December 11-14, 2021 in Atlanta, Georgia. Takedas latest research in hematologic diseases focuses on optimizing patient care, while advancing novel approaches for patients with limited or ineffective treatment options. Takeda Oncology will present data in multiple myeloma, lymphoma and leukemia from the companys marketed products as well as provide early insights into the potential of therapies leveraging the innate immune system. In hematology, Takeda will present prospective, post-hoc and real-world data across a range of hematological disorders, aimed at addressing the breadth of needs within the bleeding disorders community, while investigating potentially transformative treatment options.